Healy Comes To Defense Of NCI’s Robert Wittes; Official Has Been Target Of Innuendo Over Taxo
In Brief: James Wallace Named CALGB Executive Officer; Gritz Receives First Joseph Cullen Award
In Congress; GAO Says Some Yew Bark Lost In ’91, But Problems Are Being Corrected
NIH Scientists May Take Payment For Outside Teaching, Writing, Ethics Office Says In Final Rule
NIEHS Director Olden Outlines Strategy For Carcinogenicity Testing
RFAs Available: Silicone And Immune Response; Role Of Metallotionein; Dietary Fat Biomarkers
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
